(RTTNews) - Valneva SE (VALN) a specialty vaccine company, on Wednesday announced that it is advancing to a Phase 3 trial for IXCHIQ, its single-dose chikungunya vaccine, in children aged 1 to 11, following positive Phase 2 results.
The vaccine showed strong safety and immune response in both full and half doses, with the full dose selected for Phase 3 testing, set to begin in Q4 2025.
Dr. Juan Carlos Jaramillo, Chief Medical Officer at Valneva, stated, "These first data in children are aligned with the robust antibody response and good safety profile we reported in both adolescents and adults after a single vaccination."
IXCHIQ is the first licensed chikungunya vaccine, currently approved for adults 18 and older in the U.S., Europe, and Canada. Valneva plans to expand its use to adolescents and is seeking approval in Brazil and the UK.
The trial was supported by CEPI and the European Union, highlighting the potential for IXCHIQ to help combat chikungunya in regions with ongoing outbreaks, particularly for younger populations.
Currently, VALN is trading at $4.66 down by 1.06%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
